SNAP

AppLovin and Snap are compared as advertising-focused technology stocks for 2026. AppLovin demonstrates exceptional growth with 70% revenue increase, 60.8% net margins, and $3.9B free cash flow, while Snap serves 971M users but remains unprofitable with -7.8% net margins despite improving losses. The article recommends AppLovin due to its superior profitability and growth trajectory versus Snap's ongoing path to consistent profitability.

Snap stock declined 4.81% on October 16, 2026, outpacing the broader market's 1.09% loss. Despite recent gains of 13.98% prior to this trading day, the stock faces upcoming earnings on November 4, 2026.

Analysts expect strong year-over-year growth with EPS of $0.16 (up 166.67%) and revenue of $1.72 billion (up 14.33%). Snap trades at a Forward P/E of 10.98, below its industry average of 21.23, and holds a Zacks Rank #3 (Hold) rating.

Snap (SNAP) declined 6.01% in trading, underperforming the S&P 500's 1.11% loss. The company is set to report earnings on November 4, 2026, with analysts expecting $0.16 EPS (166.67% YoY growth) and $1.72B revenue (14.33% growth).

For the full year, consensus estimates project $0.59 EPS and $6.78B revenue. SNAP trades at a Forward P/E of 11.06, below the industry average of 20.8, and holds a Zacks Rank #3 (Hold) rating.

Hims & Hers Health (NYSE: HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company deceptively shared consumers' health data with third-party advertising platforms like Meta and Snap, and violated billing regulations by charging for prescriptions before medical consultations. The stock plunged 14.7% on July 29, 2026, erasing over $970 million in market value.

Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Hims & Hers Health, Inc. following FTC allegations that the telehealth provider shared consumers' sensitive health information with third-party advertising platforms including Meta and Snap, and engaged in deceptive billing practices. The lawsuit covers securities purchased between August 4, 2025 and July 29, 2026, with a lead plaintiff deadline of November 2, 2026. Hims & Hers shares declined nearly 15% following the FTC announcement.

Hims & Hers Health (HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company shared consumers' health data with third-party advertisers like Meta and Snap, charged for prescriptions before medical consultations, and violated ROSCA regulations. The stock dropped 14.7% on July 29, 2026, erasing over $970 million in market value. Investors with substantial losses are encouraged to participate in the class action.

Snap (SNAP) closed at $5.34, up 2.3% in the latest session, outperforming the broader market. The company is expected to report EPS of $0.16 (up 166.67% YoY) and quarterly revenue of $1.72 billion (up 14.33% YoY).

Trading at a Forward P/E of 8.9 versus the industry average of 19.04, Snap appears undervalued. However, the stock holds a Zacks Rank of #3 (Hold) with steady consensus estimates over the past month.

A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making materially false statements about its privacy practices. The FTC accused HIMS of sharing customers' medical information with third-party advertisers including Meta and Snap, and charging consumers for prescriptions without proper consultation. The stock declined 14.73% on the news, dropping $4.32 per share to $25.00 on July 29, 2026.

Meta Platforms is set to report Q3 2026 results with expected revenues of $61B-$64B, driven by strong advertising demand and AI-powered solutions like Advantage+. However, elevated capital expenditures of $130B-$145B for 2026, margin pressure, and premium valuation remain significant concerns for investors.

Robbins Geller announces a class action lawsuit against Hims & Hers Health, Inc. for allegedly sharing consumers' health information with third-party advertising platforms and charging for prescriptions immediately after intake forms despite claiming personalized consultations. The FTC filed a lawsuit on July 29, 2026, leading to a 15% decline in Hims & Hers stock. Investors with substantial losses can seek lead plaintiff status before November 2, 2026.

Robbins LLP is reminding investors of a pending class action lawsuit against Hims & Hers Health, Inc. for allegedly sharing consumers' sensitive health information with advertising platforms while claiming privacy protection, and engaging in deceptive billing practices. The FTC filed a lawsuit on July 29, 2026, which caused HIMS stock to decline 14.73%. Investors who purchased securities between August 4, 2025 and July 29, 2026 may be eligible to participate, with a lead plaintiff deadline of November 2, 2026.

cauZmik Inc is launching a new Snapchat podcast in partnership with Los Angeles-based model and creator Blaze Wilde in October 2026. The podcast will feature candid conversations about pop culture, politics, Arab identity, and Wilde's experiences living between the UAE and the United States, drawing from his modeling career and social media presence.

The article compares AppLovin and Reddit as digital advertising investment opportunities. AppLovin boasts higher profitability with 60.8% net margins and $5.5B in FY2025 revenue, but faces legal challenges and competitive pressures.

Reddit shows strong growth with 69.4% YoY revenue increase, newly achieved profitability, and a unique AI data licensing business. The author recommends Reddit for its durable growth foundation, unique data assets, and consistent user engagement, despite AppLovin's superior margins.